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Key questions
What is already known about this subject?
 ► Ultra-small superparamagnetic particles of iron 
oxide (USPIO) are ingested by tissue macrophages 
that can be visualised using MRI to highlight areas of 
macrophage inflammation within the heart.
What does this study add?
 ► Stable patients with cardiac transplantation have 
increased myocardial T2 values, consistent with 
resting myocardial oedema or fibrosis. Despite this, 
USPIO-enhanced MRI is normal and stable over 
time suggesting the absence of chronic macro-
phage-driven cellular inflammation.
How might this impact on clinical practice?
 ► USPIO-enhanced T2* MRI may still prove to be of 
value in diagnosing and monitoring conditions with 
macrophage-driven myocardial inflammation, in-
cluding acute transplant rejection with associated 
macrophage infiltration.
AbstrAct
Objectives Ultra-small superparamagnetic particles 
of iron oxide (USPIO)-enhanced MRI can detect cellular 
inflammation within tissues and may help non-invasively 
identify cardiac transplant rejection. Here, we aimed 
to determine the normal reference values for USPIO-
enhanced MRI in patients with a prior cardiac transplant 
and examine whether USPIO-enhanced MRI could detect 
myocardial inflammation in patients with transplant 
rejection.
Methods Ten volunteers and 11 patients with cardiac 
transplant underwent T2, T2* and late gadolinium 
enhancement 1.5T MRI, with further T2* imaging at 
24 hours after USPIO (ferumoxytol, 4 mg/kg) infusion, at 
baseline and 3 months.
Results Ten patients with clinically stable cardiac 
transplantation were retained for analysis. Myocardial 
T2 values were higher in patients with cardiac transplant 
versus healthy volunteers (53.8±5.2 vs 48.6±1.9 ms, 
respectively; p=0.003). There were no differences 
in the magnitude of USPIO-induced change in R2* in 
patients with transplantation (change in R2*, 26.6±7.3 
vs 22.0±10.4 s-1 in healthy volunteers; p=0.28). After 
3 months, patients with transplantation (n=5) had 
unaltered T2 values (52.7±2.8 vs 52.12±3.4 ms; p=0.80) 
and changes in R2* following USPIO (29.42±8.14 vs 
25.8±7.8 s-1; p=0.43).
Conclusion Stable patients with cardiac transplantation 
have increased myocardial T2 values, consistent with 
resting myocardial oedema or fibrosis. In contrast, 
USPIO-enhanced MRI is normal and stable over time 
suggesting the absence of chronic macrophage-driven 
cellular inflammation. It remains to be determined whether 
USPIO-enhanced MRI may be able to identify acute cardiac 
transplant rejection.
Trial registration number NCT02319278349 (https:// 
clinicaltrials. gov/ ct2/ show/ NCT02319278) Registered 
03.12.2014 EUDraCT 2013-002336-24.
InTROduCTIOn
Cardiac transplantation is a life-prolonging 
treatment for end-stage cardiac disease. 
Transplant rejection is a major threat to the 
allograft, requiring treatment in around 
one in eight transplant recipients in the 
first year1 but can occur at any stage after 
transplantation and causes significant 
morbidity and mortality. Rejection is noto-
riously difficult to diagnose using existing 
non-invasive imaging methods with repeated 
surveillance myocardial biopsies often under-
taken.
Most cases of acute rejection are due to 
cellular rejection with antibody-mediated 
rejection less prevalent. Rejection severity is 
classified according to histological findings, 
and although the cellular infiltrate in acute 
cellular rejection is predominantly lympho-
cytic, macrophage infiltration has a key 
role.2 3 The importance of macrophages in 
acute cardiac allograft rejection was recently 
emphasised in a rodent study that showed 
depletion of circulating macrophages 
protected the allograft against rejection, 
raising the possibility of therapeutic targeting 
of macrophages as a novel treatment strategy.4
Iron oxide nanoparticles are generating 
interest as a MRI contrast medium that is 
able to detect macrophages, and clinical 
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applications, such as myocardial infarction, are now 
emerging.5–11 Ultra-small superparamagnetic particles 
of iron oxide (USPIO) consist of an iron oxide core 
surrounded by a carbohydrate or polymer coating. They 
are small enough to extravasate passively through capil-
laries, where they are engulfed by tissue-resident macro-
phages12 and are detectable by T2*-weighted MRI. Thus, 
USPIO-enhanced MRI can identify tissue-resident macro-
phage activity and help to identify cellular inflammation 
within tissues.
Promising preclinical studies have shown USPIO-en-
hanced MRI is able to detect acute cardiac and renal 
allograft rejection with USPIO signal correlating with 
macrophage distribution, rejection severity on histology 
and impaired cardiac function. Moreover, this approach 
can also be used to assess treatment response with 
rodent models demonstrating less USPIO enhancement 
following initiation of immunosuppression.4 13–17 A future 
role of USPIOs includes a ‘theranostic’ strategy whereby 
imaging is combined with therapy; Guo et al18 recently 
conjugated an iron nanoparticle to a CD-3 antibody and 
a therapy gene, allowing imaging and targeting of T cells 
that play a central role in acute cardiac allograft rejection.
In this study, we aimed to assess and quantify myocar-
dial USPIO enhancement in stable patients with cardiac 
transplantation and patients with cardiac transplant rejec-
tion, correlating enhancement with clinical measures of 
inflammation and oedema including T2 mapping MRI,- 
a quantitative imaging method assessing myocardial 
oedema in transplant rejection.19 20 We hypothesised that 
USPIO-enhanced MRI would detect myocardial macro-
phage activity in the inflamed myocardium of rejecting 
transplanted hearts, but not in stable healthy cardiac 
allografts, and provide a cellular-specific non-invasive 
imaging technique that may aid and improve patient 
diagnosis and management.
MeTHOds
This was an open-label observational multicentre cohort 
study (NCT02319278) that recruited patients between 
January 2015 and May 2016. The study was performed in 
accordance with the Declaration of Helsinki, the approval 
of the Scotland A Research Ethics Committee (13-SS-
0111), and the written informed consent of all partici-
pants. The Medicines and Healthcare products Regula-
tory Authority of the United Kingdom gave Clinical Trial 
Authorisation for the study (EUDraCT 2013-002336-24).
study populations
Adult (>18 years of age) patients with a history of cardiac 
transplantation (including suspected allograft rejection) 
were recruited into the study. Healthy volunteers had no 
clinically significant medical history. Exclusion criteria 
were contraindication to MRI or ferumoxytol infusion, 
any other inflammatory comorbidity, renal failure (esti-
mated glomerular filtration rate <30 mL/min/1.73 m2), 
pregnancy, breastfeeding and women of childbearing 
potential without reliable contraception.
study protocol
Patients with cardiac transplantation and healthy volun-
teers underwent paired MRI scans at baseline, and 
patients were invited to return for repeat imaging after 
3 months. At the time of scanning, blood samples were 
collected for clinical haematology and biochemistry 
measurements.
Magnetic resonance imaging
MRI was performed using a MAGNETOM Avanto 1.5T 
MRI (Siemens Healthcare, Erlangen, Germany), with a 
dedicated cardiac array coil. All images were acquired 
with ECG gating using expiration breath-holds. Routine 
steady state free precession (TrueFISP) sequences were 
used to acquire long-axis and short-axis cine images of 
the heart (repetition time (TR) 85.8 ms, echo time (TE) 
1.45 ms, flip angle 50°, matrix 173×256, field of view 
(FoV) 400 mm, slice thickness 8 mm, 2 mm gap). Quanti-
tative USPIO imaging was performed in similar slice posi-
tions using a prototype T2*-weighted multigradient-echo 
acquisition with a volumetric shim applied over the entire 
heart volume (TR 996 ms, TE 2.13, 4.3, 6.4, 8.6, 10.7, 12.8, 
15.0, 17.1 ms, flip angle 18°, matrix 130×256, FoV 400 mm, 
slice thickness 6 mm, gap 4 mm). The T2*-weighted acqui-
sitions included views through the liver, spleen and spine 
to allow quantification of USPIO accumulation within 
organs of the reticuloendothelial system. The same 
T2* protocol was used to quantify USPIO accumulation 
24 hours after infusion allowing calculation of T2* relax-
ation rates before and after administration of USPIO. 
T2 mapping was conducted using a Siemens prototype 
T2-prepared TrueFISP acquisition acquiring identical 
long-axis and short-axis slice positions (TR 219.3 ms, TE 
1.07 ms, T2 prep durations 0, 25, 50 ms, flip angle 70°, 
matrix 130×192, FoV 400 mm, slice thickness 6 mm, 4 mm 
gap). T2P-TrueFisp images are acquired at intervals of at 
least three RR intervals to allow for sufficient magnetisa-
tion recovery in between acquisitions.
Immediately after the baseline T2 and T2*-weighted 
scan, participants received an intravenous administra-
tion of gadolinium contrast medium (0.15 mmol/kg; 
Gadovist, Bayer Plc, Germany) followed by breath-held 
inversion recovery sequences in long-axis and short-axis 
planes to acquire late-enhancement images. Optimal 
inversion time (TI) was determined on a slice-by-slice 
basis using standard late-enhancement TI-scout protocols 
(TR 750 ms, TE 2.61 ms, flip angle 20°, matrix 173×256, 
FoV 400 mm, slice thickness 9 mm, gap 1 mm). The inver-
sion-recovery late-enhancement short-axis slices were 
acquired using similar slice positions as the T2-oedema 
and T2*-weighted imaging.
ultra-small superparamagnetic particles of iron oxide
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg; 
Rienso, Takeda Italia, Italy) was performed immediately 
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Figure 1 Post-USPIO R2* and T2 maps for a healthy 
volunteer (A), patient with cardiac transplant (B) and 
myocardial infarction (C). Myocardial oedema is displayed 
as brighter signal in the T2 colour map corresponding to 
higher T2 value. Cardiac transplant myocardium (B) displays 
no USPIO accumulation but high T2, in contrast to USPIO 
accumulation and high T2 in myocardial infarction (C). 
USPIO, ultra-small superparamagnetic particles of iron oxide.
following the baseline magnetic resonance scan over 
15 min using a concentration of 2–8 mg/mL, diluted 
in 0.9% saline or 5% dextrose. Haemodynamic moni-
toring was conducted throughout, and participants were 
observed for a further 30 min to ensure no hypersensi-
tivity reactions.
Image analysis
All T2*-weighted multigradient-echo images for each 
patient were analysed using Circle CVI software (Circle 
CVI42, Canada). An experimentally determined 
threshold used in previous work6 for the coefficient of 
determination (r2 >0.85) was used to exclude data that 
did not have an acceptable exponential decay when 
signal intensity (SI) was plotted against echo time. Indi-
vidual images affected by artefact were excluded. The 
inverse of the mean T2* (R2*) for each region of interest 
(ROI) was then calculated to assess the uptake of USPIO, 
where the higher the value, the greater the USPIO accu-
mulation.
T2 maps, ventricular volume and functional anal-
yses were also performed using Circle CVI software 
(Circle CVI42, Canada). T2 and T2* data were collected 
immediately prior to USPIO administration. USPIO-en-
hanced T2* data were collected 24–25 hours following 
ferumoxytol administration. ROIs were drawn on T2 
and T2* images in the septum at midcavity level between 
anterior and inferior RV insertion points (see figure 1). 
Septal myocardial regions only were selected to reduce 
influence of artefact caused by nearby stomach or lung.21
Histology
Myocardial tissue samples were obtained from one 
patient with cardiac transplantation undergoing surveil-
lance biopsies without suspicion of transplant rejection. 
USPIO was administered 24 hours prior to the biopsy, 
and a trucut myocardial biopsy sample was taken from the 
myocardium. The biopsy sample was fixed in formalin, 
embedded in paraffin, sectioned and stained to look at 
architecture (H&E), accumulation and distribution of 
USPIO (Prussian Blue) and macrophages (CD68).
sample size and statistical analysis
Previous work has shown the change in R2* due to 
USPIO in ‘healthy’ myocardium (remote from the site 
of myocardial infarction) to be 40±11 s-1 at 24 hours 
following USPIO.6 Assuming the change due to USPIO is 
similar in truly healthy myocardium, a sample size of 10 
in each group is needed to detect an effect size of 20 s-1 
due to USPIO (ie, an increase of 50%) with 80% power 
and significance level of 0.05.
All statistical analysis was performed with GraphPad 
Prism, version 6 (GraphPad Software, San Diego, Cali-
fornia, USA). Shapiro-Wilk or D’Agostino and Pearson 
tests were used to test normality of distribution. To 
compare participant characteristics, USPIO uptake and 
myocardial oedema in patients and volunteers, R2* 
and T2 values were compared using χ2, unpaired t-tests 
and Mann-Whitney tests as appropriate depending on 
normality distribution. To compare results at 3 months 
with baseline, paired t-test and Wilcoxon test was used. 
Statistical significance was defined as two sided p<0.05.
ResulTs
Ten volunteers and 11 patients with cardiac transplanta-
tion were recruited. One volunteer was excluded from 
analysis due to the presence of LGE as described previ-
ously.21 At the time of recruitment, all transplant patients 
were assessed to be clinically well with no firm evidence 
of allograft rejection based on clinical history, examina-
tion and routine blood samples. One patient with prior 
cardiac transplant was excluded due the finding of LGE 
consistent with myocardial infarction that may influence 
the USPIO enhancement data.6 No other patient with 
cardiac transplant displayed LGE. Five of the 10 cardiac 
transplant patients returned at 3 months for repeat 
imaging. Administration of ferumoxytol was well toler-
ated with no adverse reactions reported during or imme-
diately after administration in any of the participants.
Volunteers were predominantly female and patients 
with cardiac transplant were predominantly male 
(table 1). Transplant patients had smaller indexed 
end-diastolic ventricular volumes (p<0.01) and higher 
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Table 1 Participant characteristics
Healthy 
volunteers
Patients with 
transplant
Number 9 10
Female 6 1*
Age (years) 52 (45.5–61.5) 60 (52.75–64.5)
Time since transplantation 
(months)
  59 (19–159)
Body mass Index (kg/m2) 22.9 (20.1–26.9) 25.9 (24.0–27.9)
Left ventricular end-diastolic 
volume (mL/m2)
80.9±10.4 62.9±15.5**
Left ventricular ejection 
fraction (%)
63.6±4.9 65.0±7.1
Blood tests     
  White cell count (×109/L) 6.5±1.5 6.1±2.5
  C reactive protein (mg/L) 1.9±2.0 2.1±2.1
  Plasma troponin (ng/L) 3.1±2.8 14.1±20.9*
Mean±SD or median (IQR).
*p<0.05, **p<0.01 (compared with volunteers).
Figure 2 Comparison of T2 (ms) and R2*(s-1) measurements 
at baseline in healthy volunteers (HV) and cardiac transplant 
patients (Tx). Transplant patients have higher T2 than healthy 
volunteers, but no other significant differences exist between 
groups (**p<0.01). USPIO, ultra-small superparamagnetic 
particles of iron oxide.
Table 2 Septal myocardial R2* and T2 values in healthy 
volunteers and patients with cardiac transplantation
Patients with 
transplant
Healthy 
volunteers
Pan-myocardial pre-USPIO R2* (s-1) 31.6±5.9 34.0±10.1
Pan-myocardial post-USPIO R2* (s-1) 58.2±7.5 56.0±10.2
Pan-myocardial ΔR2* (s-1) 26.6±7.3 22.0±10.4
T2 (ms) 53.8±5.2* 48.6±1.9
Mean±SD.
*p<0.01 (compared with volunteers).
USPIO, ultra-small superparamagnetic particles of iron oxide.
Figure 3 Repeated imaging in patients with cardiac 
transplant. There were no differences in myocardial T2 (ms) 
(A) or the change in R2* (s-1) (B) due to USPIO between time 
points (n=5).
baseline plasma high-sensitivity troponin concentrations 
(p<0.05). There were more males in the transplant group 
(p<0.05), but there were no other differences between 
groups at baseline.
T2 and R2* mapping
Patients with cardiac transplantation had a higher T2 
value than volunteers (53.8±5.2 vs 48.6±1.9 ms, respec-
tively, p=0.003; figures 1 and 2 and table 2). There were 
no differences in R2* between patients with cardiac 
transplantation and volunteers at baseline (31.6±5.9 vs 
34.0±10.1 s-1, p=0.84), at 24 hours after USPIO admin-
istration (58.2±7.5 vs 56.0±10.2 s-1, p=0.60) or in the 
magnitude of change in R2* due to USPIO (26.6±7.3 vs 
22.0±10.4 s-1, p=0.28; figures 1 and 2 and table 2).
There were no differences in either T2 (52.7±2.8 vs 
52.12±3.4 ms, p=0.80) or the change in R2* due to USPIO 
(29.42±8.14 vs 25.8±7.8 s-1, p=0.43) between baseline and 
3 months in patients with cardiac transplant (figure 3). 
The myocardial biopsy 24 hours after USPIO adminis-
tration revealed normal myocyte architecture with no 
evidence of increased numbers of inflammatory macro-
phages or the presence of USPIO (figure 4).
Cardiac transplant patient with recently suspected allograft 
rejection
One patient was recruited to the study 3 days following 
admission with non-specific malaise. This was the only 
patient in our cohort that had a previous history of 
previous acute cellular rejection (2 years before). On 
this occasion, the myocardial biopsy showed grade 1a 
rejection (ie, no evidence of recurrence of rejection or 
cellular infiltration), and the patient was reassured but 
subsequently recruited to the study. This patient had the 
highest plasma high-sensitivity troponin I in the cohort 
at 71 ng/L. Other blood tests were normal including 
white cell count (4.3×109/ L) and C reactive protein 
(<1 mg/L). The T2 value for this subject was the highest 
in our cohort at 66.4 ms (16-segment average of 61.8 
ms). R2* was 26.7 s-1 at baseline and 50.6 s-1 24 hours after 
USPIO: change in R2* was 23.8 s-1. A reanalysis of the data 
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Figure 4 Biopsy from patient with cardiac transplant. (A) 
H&E (×100) staining showing normal myocyte architecture 
with no evidence of significant inflammatory cell infiltration. 
(B) CD68 staining (×200) showing only very few scattered 
macrophages (brown). (C) Prussian blue staining showing no 
evidence of iron.
censoring this patient from analysis continued to show a 
higher T2 value in patients with cardiac transplantation 
than volunteers (52.4±2.8 vs 48.6±1.9 ms, p=0.0056). This 
patient did not undergo gadolinium-enhanced imaging 
at the request of the attending clinician due to mild renal 
impairment.
dIsCussIOn
For the first time, we report the combined assessment of 
T2 mapping and USPIO-enhanced T2* MRI in patients 
with prior cardiac transplantation and healthy volunteers. 
This technique is feasible, safe and well tolerated in this 
group of patients. We demonstrate that while myocar-
dial T2 is increased, there is no evidence of ongoing 
or chronic cellular inflammatory uptake as detected by 
USPIO enhancement. Further assessments of these meas-
ures are now needed in patients with acute cardiac trans-
plant rejection.
USPIO-enhanced T2* MRI has previously been used 
in man to assess cardiovascular inflammation in a range 
of different conditions,5–8 11 and preclinical models 
suggest this technique may be useful in assessing human 
patients with transplant rejection.4 13–17 In our cohort of 
stable patients with cardiac transplantation, we did not 
detect greater USPIO enhancement within the myocar-
dium, but this contrasted with the increased measures 
of myocardial T2 found in transplant patients compared 
with volunteers.
Why did we detect higher T2 values in our cohort 
of transplant patients compared with controls in the 
absence of USPIO accumulation? There are several 
plausible explanations. First, chronic residual low-grade 
inflammation or oedema without tissue-resident macro-
phage infiltration is possible, perhaps from lymphocytes 
that do not take up USPIO. In the absence of histological 
data, we cannot confirm the presence of lymphocytes, but 
in a stable group of patients who are clinically well, this 
explanation appears unlikely. Second, higher T2 values 
in the myocardium of cardiac allografts may simply be 
due to increased water content, possibly related to expan-
sion of the myocardial vasculature and blood content. 
The finding of greater measures of R2* (both at base-
line and after USPIO), which measures iron within the 
blood pool, would support this mechanism. This explana-
tion may suggest intriguing differences in the behaviour 
of resting myocardial vascular integrity in patients with 
stable cardiac allografts. Third, the relatively low field 
strength of the MRI scanner (1.5T) may be contribu-
tory since it has poorer sensitivity in detecting sparse 
myocardial USPIO compared with higher field strength 
3T scanners. However, in our single myocardial biopsy, 
substantial numbers of macrophages were not evident. 
Finally, a possible explanation for greater measures 
of T2 in cardiac allografts may in fact reflect a change 
in myocyte architecture caused by myocardial fibrosis 
or scarring. High T2 value is usually solely attributed 
to myocardial oedema but has previously been found 
to inversely correlate with LV function in patients with 
dilated cardiomyopathy that did not have any evidence of 
inflammation or other reasons for myocardial oedema.22 
This may suggest that in this cohort higher T2 values 
reflect myocardial fibrosis, similar to results using T1 
mapping techniques. Recently published data in a similar 
cohort of patients found elevation of T2 and T1 values in 
all transplanted patients, even without history of cardiac 
rejection, and the authors suggest this is due to greater 
myocardial oedema and interstitial fibrosis at baseline.23 
However, we contend that elevated T2 in the myocardium 
of cardiac allografts in this cohort may reflect intrinsic 
changes to the cellular architecture, such as the presence 
of myocardial fibrosis and not myocardial oedema. As 
such, it may prove to be a further imaging biomarker of 
myocardial fibrosis. Crucially, we lacked adequate access 
to sufficient histology or T1 mapping in order to prove 
whether subtle myocardial fibrosis, not detected by LGE 
imaging, is a causative factor in the high T2 value found. 
Most patients had undergone transplantation many years 
ago (see table 1) so using historical postoperative surveil-
lance biopsies would not provide an accurate assessment 
of current myocyte architecture.
Irrespective of the aetiology, greater T2 in stable trans-
plant patients is an interesting finding reported recently 
that we have now confirmed and warrants further 
investigation. Previous small studies have found that 
T2-weighted and T2 mapping MRI assists in diagnosis 
and prognosis estimation in patients with cardiac trans-
plant rejection.24–26 Following on from these studies, the 
DRAGET (Detection of Acute Graft Rejection in Heart 
Transplant Patients by Estimation of T2) study,27 a large 
multicentre multinational study, is now prospectively 
recruiting patients in the first year after transplantation 
to assess the performance of T2 mapping in diagnosing 
transplant rejection. The findings of this study are awaited 
with interest, but clearly if the T2 value in myocardium of 
stable cardiac allografts is raised, this increases the likeli-
hood of false-positive diagnoses of allograft rejection and 
ultimately reduces the specificity and precision of the test.
One patient had very high myocardial T2 and deserves 
special mention. This was the only patient with a previous 
history of biopsy proven acute cellular rejection 2 years 
previously. At the time of recruitment, the patient was 
recovering from a non-specific illness, and recurrent 
episode of rejection had been discounted on the basis 
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of negative endomyocardial biopsies 3 days previously. 
Based on the studies mentioned previously, myocardial 
T2 value of this magnitude suggests severe rejection. 
Serial imaging with T2 mapping, both prior and subse-
quent to this episode, would have been useful in deter-
mining the time course and fluctuation in T2 to assess 
whether it is chronically elevated, which may suggest 
stable myocardial fibrosis or not. This patient in fact 
had T1 maps acquired as part of imaging biobank reten-
tion (the only one in our study), and septal values were 
elevated at 1018 ms (normal values 950±21 ms).28 Clearly, 
we cannot make generalisations from one patient, but 
this provides further support to the argument that high 
T2 may reflect myocardial fibrosis.
Whether this patient had allograft rejection (with 
a negative biopsy) remains uncertain, but a clinical 
improvement was made with no new changes to medical 
therapy, making an episode of rejection is less likely. 
There was certainly no evidence for USPIO uptake or 
significant macrophage infiltration. If myocardial fibrosis 
and active rejection or inflammation is not the cause of 
elevated T2, then why was the T2 value so high in this 
patient? A high T2 value of this magnitude in the absence 
of rejection would cast doubt on the precision of T2 
mapping to diagnose and exclude cardiac allograft rejec-
tion and diminish its potential utility in clinical practice. 
The DRAGET study will be well placed to answer this.27
There are some limitations that deserve mention. Our 
numbers were small but sufficient for a pilot study testing 
the feasibility of USPIO-enhanced MRI in this population. 
From our recent work in patients with myocardial infarc-
tion, we know that this technique works and is capable 
of identifying and tracking myocardial macrophage accu-
mulation macrophage.5 In this study, myocardial macro-
phage infiltration is either not a chronic feature of stable 
transplants or at levels too low to be detected.
We intended to recruit a range of patients with cardiac 
transplantation, from chronic stable patients, to patients 
with suspected allograft rejection. Unfortunately, we were 
only able to recruit one patient with recently suspected 
transplant rejection, and this was excluded clinically, with 
the remaining patients being stable and well. Small study 
numbers and absence of patients with florid transplant 
rejection clearly limit our findings, and this technique 
now needs to be tested in patients with proven acute 
transplant rejection.
In conclusion, we have shown that stable patients 
with cardiac transplantation have greater measures of 
myocardial T2, which may suggest myocardial oedema 
or fibrosis, compared with control volunteers. Ferumoxy-
tol-enhanced MRI does not add clinically relevant infor-
mation in this group of stable patients, and it remains 
to be determined whether this technique may be able 
to identify macrophages in the setting of proven acute 
cellular transplant rejection.
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